CCTG Clinical Trials
Public Trial Select
Member Trial Select
Protecting Cancer Patients from COVID-19In the race to find new ways to prevent and treat COVID-19, CCTG has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients. More >> |
Recently Activated Trials
Member Links
CCTG Announces Initiation of IND.239CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer. More >> |
Planned Trials
Committees Select
CCTG is recruiting for a Patient Representative Volunteer Role
Seeking applications for a Patient Representative for the Head and Neck Disease Site Committee
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Head and Neck Disease Site Committee (cancer inside the nose, throat or mouth).
This is a volunteer role for membership on the Head & Neck General Committee, the Head & Neck Executive Committee, and the CCTG Patient Representative Committee. Patient Representatives participate in all aspects of their Site Committee activities, and collectively all Site Committee Patient Representatives make up the CCTG Patient Representative Committee.
More >>
Treating spinal lesions with fewer, higher doses of radiation reduces pain more effectively
The results show that using fewer and higher doses of high-precision radiation therapy is a more effective approach for treating painful spinal tumors than conventional radiation therapy. More than twice as many patients treated with stereotactic body radiation therapy (SBRT) reported an enduring, complete reduction in pain, compared to those treated with conventional radiation.
More >>
Dr. Cheung and Dr. Hay receive bridge funding - CIHR Spring 2020 competition
Congratulations to Dr. Annette Hay, a Senior Investigator with the Canadian Cancer Trials Group and Dr. Matthew Cheung, Hematologist at Sunnybrook Health Sciences Centre. Together they received $100,000 in bridge funding in the Canadian Institutes of Health Research (CIHR) Spring 2020 competition.
More >>
Treating spinal lesions with fewer, higher doses of radiation reduces pain more effectively
The results show that using fewer and higher doses of high-precision radiation therapy is a more effective approach for treating painful spinal tumors than conventional radiation therapy. More than twice as many patients treated with stereotactic body radiation therapy (SBRT) reported an enduring, complete reduction in pain, compared to those treated with conventional radiation.
More >>
Dr. Cheung and Dr. Hay receive bridge funding - CIHR Spring 2020 competition
Congratulations to Dr. Annette Hay, a Senior Investigator with the Canadian Cancer Trials Group and Dr. Matthew Cheung, Hematologist at Sunnybrook Health Sciences Centre. Together they received $100,000 in bridge funding in the Canadian Institutes of Health Research (CIHR) Spring 2020 competition.
More >>
CCTG Director Dr. Janet Dancey, elected to Canadian Academy of Health Sciences
The Canadian Cancer Trials Group (CCTG) is pleased to announce that our Director, Dr. Janet Dancey, has been elected to the Canadian Academy of Health Sciences (CAHS), which represents Canadian health sciences internationally and informs solutions that improve the health of all Canadians.
PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020
ENZAMET | CCTG PR17 (NCT02446405) study has been highlighted by the American Society of Clinical Oncology (ASCO) 2020 annual report as a major advance in cancer treatment. The results were first presented at ASCO 2019, the trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer.
More >>Planned trials
HD11
Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma
PAC3
Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Recently activated
CCTG is recruiting for a Patient Representative Volunteer Role
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Head and Neck Disease Site Committee (cancer inside the nose, throat or mouth).
This is a volunteer role for membership on the Head & Neck General Committee, the Head & Neck Executive Committee, and the CCTG Patient Representative Committee. Patient Representatives participate in all aspects of their Site Committee activities, and collectively all Site Committee Patient Representatives make up the CCTG Patient Representative Committee.
More >>
The rise of precision medicine
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
More >>
TAILORx | MAC12 trial showed no benefit from chemotherapy for many women with breast cancer
Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.
More >>
Asking the right questions
Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.
“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”
More >>Publications
Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience
Breast Cancer Res Treat , 2020
Dent SF;Botros J;Rushton M;Aseyev O;Levine MN;Parulekar WR;OGCOBrien P;Burnell M;Pritchard KI;Chen BE;Shepherd LE;
Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial (ONLINE)
Cancer n/a, 2020
Moku P;Shepherd L;Ali SM;Leitzel K;Parulekar WR;Zhu L;Virk S;Nomikos D;Aparicio S;Gelmon K;Drabick J;Cream L;Halstead ES;Umstead TM;Mckeone D;Polimera H;Maddukuri A;Ali A;Nagabhairu V;Poulose J;Pancholy N;Spiegel H;Chen BE;Lipton A;
The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance)
Cancer Epidemiol Biomarkers Prev 29: 1692, 2020
Cheng E;Zhang S;Ou FS;Mullen B;Ng K;Saltz LB;Niedzwiecki D;Mayer RJ;Mowat RB;Whittom R;Hantel A;Benson A;Atienza D;Messino M;Kindler H;Giovannucci EL;Van Blarigan EL;Meyerhardt JA;Fuchs CS;
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial (ONLINE)
The Lancet , 2020
Parker CC;Clarke NW;Cook AD;Kynaston HG;Petersen PM;Catton C;Cross W;Logue J;Parulekar W;Payne H;Persad R;Pickering H;Saad F;Anderson J;Bahl A;Bottomley D;Brasso K;Chahal R;Cooke PW;Eddy B;Gibbs S;Goh C;Gujral S;Heath C;Henderson A;Jaganathan R;Jakobsen H;James ND;Kanaga Sundaram S;Lees K;Lester J;Lindberg H;Money-Kyrle J;Morris S;O'Sullivan J;Ostler P;Owen L;Patel P;Pope A;Popert R;Raman R;Roder MA;Sayers I;Simms M;Wilson J;Zarkar A;Parmar MKB;Sydes MR;
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial (ONLINE)
JAMA Oncology , 2020
Sridhar SS;Blais N;Tran B;Reaume MN;North SA;Stockler MR;Chi KN;Fleshner NE;Liu G;Robinson JW;Mukherjee SD;Rahim Y;Winquist E;Booth CM;Nguyen NT;Beardsley EK;Alimohamed NS;McDonald GT;Ding K;Parulekar WR;
Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience
Breast Cancer Res Treat , 2020
Dent SF;Botros J;Rushton M;Aseyev O;Levine MN;Parulekar WR;O'Brien P;Burnell M;Pritchard KI;Chen BE;Shepherd LE;
Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial (ONLINE)
Breast Cancer Res Treat , 2020
Ho V;Pasquet R;Luo S;Chen G;Goss P;Tu D;Lazarus P;Richardson H;
Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients
Journal of Neuro-Oncology 149: 65 - 71, 2020
Climans SA;Brandes AA;Cairncross JG;Ding K;Fay M;Laperriere N;Menten J;Nishikawa R;O'Callaghan CJ;Perry JR;Phillips C;Roa W;Wick W;Winch C;Mason WP;